• Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline


  • Jonathan Kimball takes over the position of IGBA Chair (January 2023)

    The International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Jonathan Kimball, Vice President of Trade and International Affairs of the Association for Accessible Medicines (AAM), Vice-Chair IGBA and Vice Chair

    Read More
  • IGBA taking action to tackle shortages of antibiotic medicines (December 2022)

    The global generic medicines industry supplies most of the world’s antibiotic medicine and is aware of the current surge in demand of these products that is leading to shortages. The surge is driven by an unusually high rate of respiratory

    Read More
  • IGBA Releases Report on Factors Affecting the Supply of Generic Medicines (December 2022)

    The International Generic and Biosimilar medicines Association (IGBA) today released a report identifying key factors affecting the security of the global supply of generic prescription medicines.

    Read More
  • IGBA introductory statement at the Geneva Trilateral Symposium on The Covid 19 Pandemic: Response, Preparedness, Resilience, convened by WHO, WIPO and WTO (December 2022)

    The International Generic and Biosimilar Medicines Association is an international organization of national and regional associations representing manufacturers of generic and biosimilar medicines from around the world. Our industry supplies an estimated 80% of all quality-assured medicines globally and is

    Read More
  • IGBA joins the Fight the Fakes Alliance (December 2022)

    Fight the Fakes Alliance calls for a watertight global medicines supply chain.

    Read More
  • IGBA Reiterates its Yearly Call to Join the Biosimilars Movement on Advancing Access (November 2022)

    Geneva, November 14, 2022 – In the week ahead, IGBA will renew its commitment to the collaborative effort to establish worldwide biosimilar policies that deliver better health outcomes and biologics access equity for more patients. The third Global Biosimilars Week will

    Read More
  • IGBA’s CEO Advisory Committee Meets with WHO Director General and WHO Leadership (October 2022)

    The International Generic and Biosimilar Medicines Association’s (IGBA) newly established CEO Advisory Committee held its first in-person meeting in Geneva this week and had a far-reaching exchange with the World Health Organization’s (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus and other

    Read More
  • Richard Saynor and Vinita Gupta appointed Chair and Vice-Chair of IGBA CEO Advisory Committee (October 2022)

    The International Generic and Biosimilar Medicines Association (IGBA) announced today that it has appointed a Chair and Vice-Chair for its newly established Committee. Richard Saynor , CEO Sandoz, has been nominated as inaugural Chair, and Vinita Gupta , CEO Lupin, has been

    Read More
  • Global Biosimilars Week: Message of Vivian Frittelli, Chair, IGBA (October 2022)

    Read More
  • WHO-South Korea biomanufacturing training hub initiative (September 2022)

    Read More
  • Generic and Biosimilar Medicines, Central to Patient Health and Global Healthcare Policies (September 2022)

    Experts and leaders from the local and global generic and biosimilar medicines industry, Government and UN agencies, patient organizations, academia and other stakeholders are meeting from 7 to 9 September in Kuala Lumpur, Malaysia to discuss key topics affecting worldwide

    Read More
  • ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine (28 July 2022)

    MPP invites Expressions of Interest (EoI) from potential sublicensees based anywhere in the world for sublicences to manufacture and sell the cabotegravir long-acting injectable in the licensed territory.

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8


Our Mission and Vision

Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.



In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in September 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).

Contact Info


Rue de Cornavin 11
1201 Geneva, Switzerland

Telephone: +32 (0)477438729 (S. Kox)
This email address is being protected from spambots. You need JavaScript enabled to view it.  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site